Iliac Stents Market Size, Share & Industry Analysis, By Product Type (Bare-Metal Stents and Covered Stents), By Technology (Balloon-Expandable Stents and Self-Expanding Stents), By Application (De Novo Iliac Disease, Restenotic Iliac Disease, Iliac Aneurysms, Iliac Arterial Injury, and Others), By End-user (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast, 2026-2034

The global iliac stents market size was valued at USD 720.1 million in 2025. The market is projected to grow from USD 762.7 million in 2026 to USD 1,223.4 million by 2034, exhibiting a CAGR of 6.10% during the forecast period.

An iliac stent is a small, expandable metal wire mesh tube placed inside an iliac blood vessel in the pelvis. The stent helps to keep the blood vessel open and restore healthy blood flow. The global market growth is attributed to the continued shift toward the endovascular management of aortoiliac disease.

2025. L. Gore & Associates, Inc., BD, Boston Scientific Corporation, Medtronic, and Abbott held the highest market share in 2025. Broad product portfolio and significant investment in product advancements are major aspects driving the dominant market positions of these companies.

ILIAC STENTS MARKET TRENDS

Growing Adoption of Advanced Iliac Stent Platforms to Emerge as a Key Trend

Currently, there has been a shift toward low-profile, balloon-expandable, covered, and bifurcation-capable stents that offer easier delivery, accurate placement, and strong vessel support. As a result, key players focus on more precise and versatile stent solutions for complex iliac anatomy to enhance clinical outcomes.

• In April 2024, Getinge secured European Union Medical Device Regulation (EU MDR) certification for its Advanta V12 Covered Stent System for applications including aortoiliac disease and aortic bifurcation lesions.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising PAD Burden and Endovascular Iliac Revascularization Demand to Fuel Market Growth

Over the past few years, the increasing prevalence of peripheral artery disease (PAD) and the soaring preference for minimally invasive endovascular procedures are driving iliac stents market growth. As more patients undergo iliac revascularization, the demand for stents is increasing, particularly for complex lesions where covered stents may be preferred. For instance, a 2026 analysis by the U.S. Department of Veterans Affairs reported that vascular surgery community care referrals nearly tripled between FY2020 and FY2025. Furthermore, payments for iliac endovascular interventions increased from USD 1.65 million to USD 5.6 million during this period.

MARKET RESTRAINTS

High Costs and Procurement Pressure May Limit Market Expansion

The market growth is restrained by high device costs, hospital purchasing pressure, and the need to prove the added clinical value of premium stents. Hospitals and ASCs must balance treatment outcomes with device pricing, reimbursement limits, and purchasing contracts.

Covered and advanced stents can provide benefits in complex iliac disease, but studies do not show clear superiority for every type of lesion or clinical outcome. As a result, hospitals may continue using lower-cost conventional stents for simpler cases, while premium covered stents are adopted more selectively. Such a scenario is anticipated to hinder the market growth.

MARKET OPPORTUNITIES

Covered Stent Penetration in Complex Iliac Lesions to Create Lucrative Growth Opportunities

Covered stents offer a major growth opportunity for market players, especially for longer and more complex iliac lesions. According to data published by the European Journal of Vascular and Endovascular Surgery, in September 2024, a meta-analysis reported 48-month primary patency of 92.4% for covered stents compared to 80.8% for bare-metal stents in complex Trans-Atlantic Inter-Society Consensus (TASC)/D lesions. These results support the wider use of covered stents in complex, restenotic, and high-risk iliac disease, creating a strong opportunity for manufacturers with advanced covered stent portfolios.

MARKET CHALLENGES

High Regulatory and Compliance Requirements to Challenge the Market Growth

Iliac stents are implantable vascular devices and face strict regulatory, clinical, and quality requirements. Manufacturers must meet requirements related to clinical evidence, sterility, biocompatibility, quality management, and post-market monitoring.

In the U.S., the FDA requires premarket review and ongoing post-market controls, while updated quality system requirements aligned with ISO 13485:2016 came into effect in February 2026. In Europe, the MDR has also increased requirements for clinical evidence, post-market follow-up, and device vigilance. Although these rules improve patient safety, they can increase development costs, delay product launches, and make geographical expansion more difficult for manufacturers.

Segmentation Analysis

By Product Type

Bare-Metal Stents Segment Captured Major Share driven by Lower Cost and Wider Availability

Based on product type, the market is segmented into bare-metal stents and covered stents.

The bare-metal stents segment accounted for the largest market share in 2025. The segment growth is attributed to their lower cost, wide availability, established clinical use, and ability to provide adequate vessel support in many iliac artery procedures. Furthermore, key players are expanding their bare-metal stent portfolios, which is expected to increase product penetration globally.

To know how our report can help streamline your business, Speak to Analyst

The covered stents segment is projected to grow at a CAGR of 7.9% during the forecast period.

By Technology

Balloon-Expandable Stents Segment Led the Market owing to Suitability for Common Iliac and Aortoiliac Bifurcation Lesions

By technology, the market is segmented into balloon-expandable stents and self-expanding stents.

The balloon-expandable stents segment accounted for the largest market share in 2025. The segment growth is supported by precise placement, strong radial support, and suitability for common iliac and aortoiliac bifurcation lesions. Moreover, clinical literature notes that balloon-expandable stents are often preferred for ostial and calcified common iliac lesions due to their higher radial force and predictable deployment enable accurate treatment of focal lesions. For instance, the SENS-ILIAC randomized trial, published in December 2024 and involving 201 patients across 17 centers, reported that the common iliac artery accounted for 75.1% of target lesions. The study also reported 99.0% 1-year clinical patency in both the balloon-expandable and self-expanding stent groups, demonstrating their strong clinical effectiveness in iliac interventions.

The self-expanding stents segment is anticipated to grow at a CAGR of 5.3% over the forecast period.

By Application

Large Number of Stenting Procedures Performed for Treating Newly Diagnosed Atherosclerotic Conditions to Spur De Novo Iliac Disease Segment Growth

By application, the market is classified into De Novo iliac disease, restenotic iliac disease, iliac aneurysms, iliac arterial injury, and others.

The De Novo iliac disease segment accounted for the largest iliac stents market share in 2025 with a rise in the number of stenting procedures. Most iliac stenting procedures are performed to treat newly diagnosed atherosclerotic narrowing or blockage in the common or external iliac arteries. The segment growth is supported by the continued use of endovascular revascularization for symptomatic PAD patients. The segment is set to hold a 78.6% share in 2026.

The restenotic iliac disease segment is expected to grow at a CAGR of 7.8% during the forecast period.

By End-user

Higher Volume of Stenting Procedures Pushed Hospitals & ASCs Segment Dominance

On the basis of end-user, the market is segmented into hospitals & ASCs, specialty clinics, and others.

In 2025, the hospitals & ASCs segment dominated the market. Iliac stenting requires fluoroscopic imaging, endovascular equipment, inventory management, sterile procedure infrastructure, and trained vascular/interventional specialists. These requirements result in a huge number of procedures performed at hospitals and ambulatory surgical centers due to availability of equipment and infrastructure. The segment is set to hold a 90.4% market share in 2026.

The specialty clinics segment is projected to grow at a CAGR of 8.9% during the forecast period.

Iliac Stents Market Regional Outlook

Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America accounted for the largest share in 2024, valued at USD 288.1 million, and maintained its leading position in 2025, with a valuation of USD 301.7 million. The dominance is supported by a high burden of PAD, strong availability of vascular specialists, advanced hospital infrastructure, and the widespread use of minimally invasive endovascular procedures.

• For instance, according to data from the American Heart Association, Inc. in May 2024, the 2024 U.S. PAD guidelines recommend revascularization for appropriate symptomatic patients, supporting continued iliac stent utilization.

U.S. Iliac Stents Market

In 2026, the U.S. market is anticipated to reach USD 295.9 million, accounting for approximately 38.8% of the global sales.

Europe

The Europe market is projected to record a CAGR of 5.5% during the forecast period, the second-highest globally. The market is expected to reach USD 206.8 million in 2026. The regional market growth is supported by its aging population, established vascular-care networks, and strong adoption of endovascular treatment.

Germany Iliac Stents Market

The Germany market is projected to reach USD 44.8 million in 2026, representing approximately 5.9% of global sales.

U.K. Iliac Stents Market

The U.K. market is expected to reach USD 34.5 million in 2026, accounting for approximately 4.5% of global revenues.

Asia Pacific

In 2026, the Asia Pacific market is projected to reach approximately USD 178.2 million, making it the third-largest market. The regional market growth is due to its large patient population, rising PAD burden, improving healthcare infrastructure, and increasing availability of endovascular procedures.

Japan Iliac Stents Market

The Japan market is projected to reach approximately USD 42.6 million in revenue in 2026, representing nearly 5.6% of the global sales.

China Iliac Stents Market

In 2026, the China market is anticipated to reach USD 51.9 million, accounting for approximately 6.8% of the global sales.

India Iliac Stents Market

In 2026, the India market is anticipated to reach USD 20.2 million, accounting for approximately 2.6% of the global sales.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa markets are anticipated to witness moderate growth during the forecast period. The Latin America market is estimated to reach approximately USD 32.3 million in 2026. The market expansion in Latin America is supported by the growth  of private hospitals, vascular treatment centers, and access to minimally invasive procedures to support iliac stent demand. The market growth in the Middle East & Africa is mainly due to the increasing availability of endovascular treatment, particularly in the GCC and South Africa.

GCC Iliac Stents Market

In 2026, the GCC market is estimated to reach approximately USD 12.1 million, representing around 1.6% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Leading Players’ Strong Operations and Focus on Strategic Initiatives to Strengthen their Market Foothold

In 2025, W. L. Gore & Associates, Inc., BD, Boston Scientific Corporation, Medtronic, and Abbott held the leading market share. The dominance of these companies is attributed to their strong operations in developed countries, which supports their product availability on large scale. Other prominent players are focusing on strategic initiatives such as collaborations, mergers, and acquisitions to capture a significant market share during the forecast period.

LIST OF KEY ILIAC STENTS COMPANIES PROFILED

• L. Gore & Associates, Inc. (U.S.)
• BD (U.S.)
• Boston Scientific Corporation (U.S.)
• Medtronic (Ireland)
• Abbott (U.S.)
• Cordis (U.S.)
• Getinge (Sweden)
• Cook (U.S.)
• Teleflex Incorporated (U.S.)
• Bentley (Sweden)

KEY INDUSTRY DEVELOPMENTS

• October 2025: Getinge received additional CE Mark approval for Advanta V12 in major bridging indications and cited nearly one million devices implanted globally.
• July 2025: Teleflex Incorporated completed the acquisition of BIOTRONIK's Vascular Intervention business, strengthening its peripheral vascular product platform.
• January 2025: Bentley launched BeFlow at LINC 2025 as a dedicated iliac occlusive disease solution.
• November 2024: Getinge received EU MDR approval for Advanta V12, including aortoiliac occlusive disease and lesions at the aortic bifurcation. 
• March 2023: Getinge iCast covered stent received FDA PMA approval for symptomatic atherosclerotic disease of native common and/or external iliac arteries.

REPORT COVERAGE

The global iliac stents market report provides an in-depth analysis of the market, covering major segments and key drivers, restraints, opportunities, challenges, and trends influencing market growth. It also evaluates key industry developments, the prevalence and incidence of relevant vascular conditions, the competitive landscape, the market shares of key companies, and detailed profiles of leading market participants.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1: Revenues and Market Share of Major Iliac Stent Players

• Collection of peripheral vascular and iliac-stent-related revenues from annual reports, SEC filings, investor presentations, company disclosures, and product portfolios of W. L. Gore, BD, Boston Scientific, Medtronic, Abbott, Cordis, Getinge, Cook Medical, Teleflex, Bentley, Terumo, and other players
• Estimation of iliac-stent-attributable revenues based on product portfolio, geographical presence, regulatory approvals, hospital penetration, unit volumes, and manufacturer ASPs
• Triangulation of company revenues and estimated market shares with country-level iliac intervention demand

Approach 2: Procedure Volume and Product-Level Sales Analysis

• Estimation of iliac endovascular revascularization procedures, stenting rates, and average number of stents used per procedure across major countries
• Mapping of utilization across bare-metal, covered, balloon-expandable, and self-expanding stents and key commercial products such as VIABAHN VBX, LifeStream, Epic, Visi-Pro, Omnilink Elite, Advanta V12, and other platforms
• Multiplication of procedure volumes × stenting rate × stents per procedure × manufacturer ASP to estimate country and regional markets

Approach 3: Disease Burden, Eligible Population & Treatment Penetration Model

• Assessment of peripheral artery disease and clinically significant aortoiliac disease populations across countries
• Estimation of diagnosed, symptomatic, treatment-eligible, and endovascularly treated patient populations
• Application of iliac stenting penetration, treatment frequency, device utilization, and ASP assumptions to derive country-level market values

2. Top-Down Approaches

Approach 4: Per-Capita Spending & Peripheral Vascular Device Demand Analysis

• Analysis of country-level healthcare expenditure, medical-device spending, cardiovascular intervention spending, insurance coverage, and endovascular treatment access
• Adjustment for PAD prevalence, aging population, physician availability, hospital infrastructure, reimbursement, technology adoption, and relative device pricing
• Estimation of the iliac stent portion of relevant peripheral vascular device expenditure and validation against bottom-up estimates

Approach 5: Peripheral Intervention / Parent-Market Cross-Check

• Assessment of the broader peripheral vascular intervention device market and iliac intervention share based on procedure volumes, anatomical distribution, product utilization, and device mix
• Exclusion of venous stents, femoropopliteal-only stents, balloons, atherectomy devices, EVAR systems, and other out-of-scope products
• Comparison with company-level and procedure-based results to identify potential overestimation or underestimation

3. List of Key Sources

• S. FDA, European Commission/EU MDR, PMDA, NMPA, CDSCO, TGA
• Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), SCAI, CIRSE, and national vascular societies
• WHO, OECD, World Bank, Eurostat, national health ministries and reimbursement databases
• Hospital/procedure databases, vascular registries, PAD studies, clinical guidelines, and peer-reviewed literature
• Annual reports, SEC filings, investor presentations, product catalogs, IFUs, regulatory filings, clinical studies, approvals, and company press releases

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents:
  • Iliac/peripheral stent manufacturers, product managers, regional sales heads, business-development executives, distributors, regulatory specialists, market-access professionals, manufacturing executives, and hospital procurement representatives.

Demand Side Interviews: 40%

• Key Respondents:
  • Vascular surgeons, interventional radiologists, interventional cardiologists, hospital cath-lab professionals, vascular-center administrators, procurement managers, reimbursement specialists, and other clinicians involved in iliac revascularization.

5. Final Triangulation

• Compared results from company revenues, procedure volumes, eligible-patient modeling, per-capita spending, and parent-market analysis
• Reconciled differences in procedure penetration, ASPs, product mix, and regional adoption
• Validated historical estimates for 2021–2025 and forecast 2026–2034 using PAD/aortoiliac disease trends, endovascular procedure growth, covered-stent penetration, product launches, reimbursement changes, and emerging-market adoption
• Used the triangulated output as the final global, regional, country, segment, and company-share market estimate